Is menopause hormone therapy safe? Benefits and risks in 2026

For most healthy women who start it before age 60 or within about ten years of their last period, menopause hormone therapy is considered safe, and it remains the most effective treatment for hot flashes and night sweats. The risks that made headlines after 2002, mainly blood clots, stroke and breast cancer, are real, but they depend heavily on your age when you start, how far past menopause you are, which hormones you take and how they enter your body. In late 2025 the FDA moved to remove the broad boxed warnings from most hormone therapy labels, reflecting that more precise picture.

That is the short answer. The rest of this guide explains where the fear came from, what changed, and how to tell whether hormone therapy fits you.

What the WHI found, and what it got wrong

The Women's Health Initiative (WHI) was a large, NIH funded set of randomized trials that tested hormone therapy in postmenopausal women. It had two hormone arms:

The headlines were dramatic, and prescriptions dropped sharply almost overnight. A generation of women went without treatment for symptoms that hormone therapy relieves well.

The trial data were not wrong. The way they were generalized was. WHI enrolled women from their 50s to their late 70s, and many participants were well over a decade past menopause when they started. It tested one oral estrogen and one synthetic progestin. Those results were then applied to every woman, of every age, on every product.

Later analyses broke the results down by age and time since menopause. Women who started closer to menopause had lower absolute risks than women who started years later. And in the estrogen only arm, women did not show the increase in breast cancer seen in the combined arm. The lesson is not that hormone therapy is risk free. It is that risk is personal.

The timing window: age and years since menopause

The single biggest factor in hormone therapy safety is when you start. The Menopause Society's 2022 hormone therapy position statement concludes that for women without contraindications who are younger than 60 or within 10 years of menopause onset, the benefits generally outweigh the risks for treating bothersome symptoms and preventing bone loss.

The likely reason is biological. Blood vessels that have gone many years without estrogen respond differently when it is reintroduced, so starting late carries more cardiovascular risk than starting early.

Your situation How benefits and risks generally balance
Under 60, or within about 10 years of your last period Most favorable for healthy women with symptoms. Benefits usually outweigh risks.
60 or older, or more than 10 years past menopause Higher absolute risk of heart disease, stroke, clots and dementia. Starting systemic therapy needs careful individual review; vaginal estrogen is often still reasonable.
Already on therapy and getting older Not an automatic reason to stop. Dose, route and need are reassessed regularly with your clinician.

The Menopause Society does not recommend stopping hormone therapy at an arbitrary age such as 65. Some women continue longer because symptoms persist or bone protection matters, provided the decision is reviewed periodically.

Benefits: hot flashes, sleep, bone and vaginal health

A decade ago, most women were told to wait menopause out. In 2026, the conversation is about what you gain by treating it.

Be clear on the limits. Hormone therapy is not approved to prevent heart disease or dementia, and it should not be started for those reasons alone.

Risks: clots, stroke and breast cancer by route

How a hormone enters your body changes its risk profile. Oral estrogen passes through the liver first, which increases production of clotting factors. Estrogen absorbed through the skin largely avoids that first pass.

Type and route Blood clots and stroke Breast cancer Key notes
Oral estrogen (pill) Increased risk, seen clearly in WHI Depends on whether a progestogen is added Effective and inexpensive; less suited to women with clot risk factors
Transdermal estrogen (patch, gel, spray) Observational studies show lower clot risk than oral at standard doses Depends on whether a progestogen is added Often preferred for women with migraine, higher BMI or clot risk factors; not yet confirmed by a large randomized trial
Estrogen plus progestogen (women with a uterus) Reflects the estrogen route Small increase linked to combined therapy, rising with longer use Progestogen is essential to protect the uterine lining
Estrogen only (no uterus) Reflects the estrogen route No increase seen in the WHI estrogen only arm Not used alone if you still have a uterus
Low dose vaginal estrogen Minimal systemic absorption; no clear clot signal No clear signal in observational data Treats local symptoms, not hot flashes

A few points matter here:

FDA label changes explained

In November 2025 the FDA announced it would remove the boxed warnings, often called black box warnings, about cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy labels. Those warnings were added after the WHI and applied to every product and every age group, including low dose vaginal estrogen.

What stayed: the boxed warning about endometrial cancer for estrogen only products in women who have a uterus. The other risks did not disappear either. They remain described in the labels' warnings and precautions sections, where they can be explained with context about age, timing and dose.

What this means for you:

We break down the details in our explainer on the FDA menopause hormone therapy label changes.

Who should not take HRT, and how monitoring helps

Systemic hormone therapy is generally not appropriate if you have:

Some women in these groups can still use low dose vaginal estrogen or nonhormonal options after a specialist review. If any of these apply to you, that conversation belongs with a clinician who knows your full history.

Monitoring is what turns hormone therapy from a guess into a plan. That means baseline blood work, blood pressure, up to date breast screening, attention to any unusual bleeding, and a regular reassessment of dose, route and whether you still need treatment. Menopause is usually diagnosed from your symptoms and cycle history, but labs help rule out look alikes such as thyroid problems and give you a baseline. See what to test before treating hormones after 40.

At BioCure Health, a physician-led telehealth longevity clinic based in the Fort Lauderdale area, evaluation starts with a short online intake and a $199 video consultation with a physician, which can be credited back with a membership. Our Comprehensive Female panel covers hormones, thyroid, lipids, metabolic and organ markers, collected through an at home kit with an in home phlebotomist or at a lab, with results in 7 to 14 days. Every result is reviewed with a specialist in a 1:1 session before any protocol is set. We are licensed in 47 states, with availability confirmed at intake, and you can be seen in person or by video. We do not bill insurance directly, but many patients use HSA or FSA funds, and we provide documentation for reimbursement.

Frequently asked questions

Is HRT safe if I am over 60?

Starting systemic hormone therapy after 60, or more than 10 years after menopause, carries higher absolute risks of heart disease, stroke and clots. It is not ruled out, but it needs a careful individual review, and lower doses, transdermal routes or vaginal estrogen are often preferred. Women who started earlier and are doing well do not automatically need to stop at 60 or 65.

Does hormone therapy cause breast cancer?

Combined estrogen plus progestogen is linked to a small increase in breast cancer risk that grows with longer use. In the WHI, estrogen only therapy in women without a uterus did not show that increase. Your personal and family history matters more than any headline figure.

Is the estrogen patch safer than the pill?

Observational studies show transdermal estrogen carries a lower risk of blood clots than oral estrogen at standard doses, because it avoids the liver's first pass. That has not yet been confirmed in a large randomized trial. For women with clot risk factors, many clinicians prefer the patch or gel.

Did the FDA remove the black box warning on HRT?

In November 2025 the FDA announced it would remove boxed warnings about heart disease, breast cancer and probable dementia from menopausal hormone therapy labels. The boxed warning about endometrial cancer remains for estrogen only products in women with a uterus. Labels update product by product as manufacturers revise them.

Do I need progesterone if I take estrogen?

If you still have a uterus, yes. Estrogen without enough progestogen raises the risk of endometrial cancer, and prescribed progestogen protects the uterine lining. Over the counter progesterone creams have not been shown to provide reliable protection.

How long can I stay on hormone therapy?

There is no fixed cutoff. The Menopause Society does not recommend stopping at an arbitrary age; instead, you and your clinician should review symptoms, risks and goals regularly and adjust dose or route as you age.

Menopause hormone therapy is neither the danger it was painted as in 2002 nor a fit for every woman. The right answer for you depends on your age, your history and a plan that is monitored rather than guessed at. Longevity is not accidental, it is intentional.

Let BioCure Health lead you in the right direction. Call or text us to schedule an introductory call at 754-206-0838. Your future self will thank you.